The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.

Start Date02 Sep 2020

Sponsor / Collaborator

Virginia Commonwealth University

[+1]

NCT04447469 / CompletedPhase 2/3

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

Start Date27 Jul 2020

Sponsor / Collaborator

Kiniksa Pharmaceuticals Ltd.

NCT04397497 / Unknown statusPhase 2

A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)

This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab or placebo, in addition to standard of care per local practice. The total trial duration will be 12 weeks after single mavrilimumab or placebo dose.

Start Date22 May 2020

Sponsor / Collaborator

Ospedale San Raffaele Srl

100 Clinical Results associated with Mavrilimumab

100 Translational Medicine associated with Mavrilimumab

100 Patents (Medical) associated with Mavrilimumab

Literatures (Medical) associated with Mavrilimumab

02 Sep 2022·Expert opinion on investigational drugsQ2 · MEDICINE

Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?

Q2 · MEDICINE

Review

Author: Harkins, Patricia ; Conway, Richard

INTRODUCTION:

Giant Cell Arteritis (GCA) is the most common systemic vasculitis worldwide. For decades, glucocorticoids have represented the mainstay of treatment, at the expense of toxic systemic effects owing to prolonged courses of high-dose treatment regimens. The search for effective drugs permitting lower glucocorticoid treatment regimens in GCA has been afrustrating one. The recent successful therapeutic application of tocilizumab, an interleukin-6 receptor inhibitor, has transformed the treatment of GCA and catalyzed research exploring other promising therapeutic targets.

AREAS COVERED:

This review explores emerging drugs in preclinical and clinical development for the management of GCA, in addition to synthesizing data on the current standard of care therapeutic agents. Drug therapies were identified by search of MEDLINE and PubMed in addition to trials from registries (clinicaltrials.gov, clinicaltrialsregister.eu, pubmed.gov) from theyear 2010.

EXPERT OPINION:

Tocilizumab has revolutionized the treatment of GCA. However, much remains to be learned about its optimal usage in GCA and asubstantial minority of pa tients do not achieve sustained glucocorticoid-free remission. Numerous exciting new agents are under investigation to fill this treatment gap in GCA, with the GM-CSF inhibitor mavrilimumab, and IL-12/23 blockade with ustekinumab providing promise through targeting the GCA pathogenic pathway in its proximal portion.

01 Sep 2022·Annals of the rheumatic diseases

Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli

Article

Author: Cavalli, Giulio ; Dagna, Lorenzo ; Campochiaro, Corrado ; Zangrillo, Alberto ; De Luca, Giacomo ; Della-Torre, Emanuel ; Ciceri, Fabio

A polemic in response to Ferraccioli et al is given.This article describes the open-label trials with sarilumab, tocilizumab, anakinra and mavrilimumab in patients with severe hyperinflamed COVID-19.In this article the IL-1 or GM-CSF seems a more promising approach since upstream blockade of the inflammatory cascade may allow a better control of cytokine storm-induced organ damage with a better safety profile are discussed.

06 Jun 2022·Polish archives of internal medicine

Recent advances in the diagnosis and therapy of large vessel vasculitis

Article

Author: Soy, Mehmet ; Atagunduz, Pamir ; Keser, Gokhan

Large vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), causes granulomatous vascular inflammation mainly in large vessels, and is the most common primary vasculitis in adults. Vascular inflammation may evoke many clinical features including vision impairment, stroke, limb ischemia, and aortic aneurysms. The best way to diagnose LVV is to combine medical history, physical examination, various laboratory tests, and imaging modalities. Progress in imaging modalities facilitated early diagnosis and follow‑up of the disease activity. Conventional angiography is no longer the gold standard for the diagnosis of TAK. Similarly, temporal artery biopsy is no longer the only tool for diagnosing cranial GCA. In selected cases, color Doppler ultrasound may be used for this purpose. Despite some similarities, TAK and GCA differ in many aspects and they are different diseases. They also have different clinical subtypes. The presence of aortitis does not always implicate the diagnosis of TAK or GCA; infectious aortitis, as well as noninfectious aortitis associated with other autoimmune rheumatic diseases should be excluded. Treatment of LVV includes glucocorticoids (GCs), conventional immunosuppressive agents, and biological drugs. Tumor necrosis factor inhibitors are ineffective in GCA but effective in TAK. On the other hand, tocilizumab may be used to treat both diseases. Promising targeted therapies evaluated in ongoing clinical trials include, for example, anti‑IL‑12/23 (ustekinumab), anti‑IL‑17 (secukinumab), anti‑IL‑1 (anakinra), anti‑IL‑23 (guselkumab), anti‑cytotoxic T‑lymphocyte antigen 4 (abatacept), Janus kinase inhibitors (tofacitinib and upadacitinib), anti‑granulocyte / macrophage colony‑stimulating factor (mavrilimumab), and endothelin receptor (bosentan) therapies.

News (Medical) associated with Mavrilimumab

24 Jun 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with National Hockey League (NHL) Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease. The campaign will kick off in September of this year. Pericarditis is marked by a profound inflammation of the pericardial tissue in the multi-layered sac that surrounds the heart. The associated sharp chest pain frequently requires urgent care and hospitalization, and patients often believe they are having a heart attack. Patients experiencing recurrent pericarditis flares suffer wide-ranging effects on quality of life, physical activity, and overall well-being. “Despite the significant impact of recurrent pericarditis on patients’ lives, the limited understanding of the disease often results in delayed diagnosis and treatment,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are honored to collaborate with Henrik Lundqvist to raise awareness of the realities of suffering from recurrent pericarditis. We believe this collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares.” For more information on recurrent pericarditis, visit whatispericarditis.com. To learn about the first and only U.S. Food and Drug Administration-approved therapy for recurrent pericarditis, visit arcalyst.com. About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.Medicines that affect the immune system may increase the risk of getting cancer.Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the timing of the campaign, our belief that our collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

Vaccine

17 Jun 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality – HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis. “We are proud to sponsor the American Heart Association’s Addressing Recurrent Pericarditis initiative. Recurrent pericarditis is a rare, chronic, flaring disease, in which patients are frequently misdiagnosed or undertreated due to a lack of access to expert care. In addition to elevating awareness and knowledge around recurrent pericarditis, this initiative will also help strengthen overall care by working to improve processes for diagnosing, referring, and treating patients,” said John F. Paolini, M.D., Ph.D., FACC, Chief Medical Officer of Kiniksa. “Furthermore, this initiative will facilitate knowledge-sharing across a collaborative network of healthcare providers, with the objective of establishing a clear model to streamline patient access to expert care and improved outcomes nationwide.” Through the Addressing Recurrent Pericarditis initiative, the American Heart Association will establish a learning collaborative of champions at fifteen healthcare sites for recurrent pericarditis care. These champions will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions. The ultimate goal of the initiative is to improve outcomes and quality of life for recurrent pericarditis patients by disseminating best practices through national education, model sharing, abstract development, and patient- and physician-targeted podcasts and webinars. “Recurrent pericarditis symptoms can have significant impact on emotional health and quality of life, but they often go undiagnosed and untreated,” said Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer of the American Heart Association. “This new initiative will share insights and best practices nationally to improve identification and treatment for patients with this disease.” Participating sites in the learning collaborative include: Ascension St. Thomas Heart (Nashville, Tennessee)Bluhm Cardiovascular Institute, Northwestern Medicine (Chicago, Illinois)Brigham & Women’s Hospital (Boston, Massachusetts)Cleveland Clinic (Cleveland, Ohio)Houston Medical Hospital (Houston, Texas)Knight Cardiovascular Institute Cardiology Clinic, Oregon Health & Science University (Portland, Oregon)Massachusetts General Hospital (Boston, Massachusetts)Mayo Clinic – Rochester (Rochester, Minnesota)My Cardiologist/CVAUSA (Miami, Florida)New York University Grossman School of Medicine (New York, New York)Pacific Heart Institute (Santa Monica, California)The Regents of the University of California Irvine (Irvine, California)University of Michigan (Ann Arbor, Michigan)University of Utah Hospital (Salt Lake City, Utah)University of Virginia (Charlottesville, Virginia) About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data shows that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the ultimate number of healthcare sites that will participate in the learning collaborative; our belief that the Addressing Recurrent Pericarditis initiative will (a) improve quality of care through identification, dissemination and implementation of best practices for the diagnosis and management of recurrent pericarditis, (b) elevate awareness and knowledge around recurrent pericarditis, (c) strengthen overall care by working to improve processes for diagnosing, referring and treating patients, and (d) facilitate knowledge-sharing across a collaborative network of healthcare providers to streamline patient access to expert care and improve outcomes nationwide; that the healthcare champions participating in the Addressing Recurrent Pericarditis initiative will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions with the ultimate goal of improving outcomes, quality of life, identification and treatment for recurrent pericarditis patients by disseminating insights and best practices; and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

AHA

07 May 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ®Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

100 Deals associated with Mavrilimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09930	Mavrilimumab	-	DB12534

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
SARS-CoV-2 acute respiratory disease	Phase 3	CL	Kiniksa Pharmaceuticals Ltd.	16 May 2021
Inflammation	Phase 3	US	Kiniksa Pharmaceuticals Ltd.	16 Jul 2020
COVID-19	Phase 2	IT	Ospedale San Raffaele Srl	22 May 2020
Respiratory Distress Syndrome, Adult	Phase 2	IT	Ospedale San Raffaele Srl	22 May 2020
Respiratory Failure	Phase 2	US	Kiniksa Pharmaceuticals Ltd.	20 May 2020
Giant Cell Arteritis	Phase 2	US	Kiniksa Pharmaceuticals Ltd.	20 Sep 2018
Giant Cell Arteritis	Phase 2	AU	Kiniksa Pharmaceuticals Ltd.	20 Sep 2018
Giant Cell Arteritis	Phase 2	BE	Kiniksa Pharmaceuticals Ltd.	20 Sep 2018
Giant Cell Arteritis	Phase 2	HR	Kiniksa Pharmaceuticals Ltd.	20 Sep 2018
Giant Cell Arteritis	Phase 2	EE	Kiniksa Pharmaceuticals Ltd.	20 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03827018 (CTgov)	Phase 2	Giant Cell Arteritis	70	prednisone+mavrilimumab (Mavrilimumab)	nkzurpwukg(kfsgocjtlw) = ilddmnjipy rfihhpjsyc (ntjjhlnfpd, etcqjqpkqm - zvkppkoysg) View more	-	17 Oct 2023
				placebo+prednisone (Placebo)	nkzurpwukg(kfsgocjtlw) = zupfadidgf rfihhpjsyc (ntjjhlnfpd, gfnnmvkmyv - byvdqehpxi) View more
NCT03827018 (Pubmed) Manual	Phase 2	Giant Cell Arteritis	70	mavrilimumab	daqdmsixlg(tghqbzklrj) = zfemdwoggu mzyhlencpk (ekwwgwmkpt ) View more	Positive	09 Mar 2022
				Placebo	daqdmsixlg(tghqbzklrj) = iaovbhwcks mzyhlencpk (ekwwgwmkpt ) View more
NCT04463004 (CTgov)	Phase 2	Respiratory Failure \| COVID-19 \| Inflammation	2	Mavrilimumab (Intervention)	nwomkjdtsn(mquiazuhax) = vcvlozorse uaghuglsyt (clkxbwnsdb, ufvogveyas - mgdygjsllo) View more	-	11 Aug 2021
				Placebos (Control)	nwomkjdtsn(mquiazuhax) = ihbvobeijf uaghuglsyt (clkxbwnsdb, qnysboozge - smgyycxncn) View more
EULAR2021	Phase 2	Giant Cell Arteritis	70	Mavrilimumab 150 mg	ixxawmzyxs(cloqdzbrxk) = elpyauvhjs xqadqedxmo (oicauxqpdd, 67.9 - 91.6)	Positive	02 Jun 2021
				Placebo	ixxawmzyxs(cloqdzbrxk) = bqbdkudjqq xqadqedxmo (oicauxqpdd, 29.6 - 67.3)
Phase 2 Trial of Mavrilimumab (EULAR2021)	Phase 2	Giant Cell Arteritis C-reactive protein \| erythrocyte sedimentation rate	70	Mavrilimumab 150mg	ynugbcrain(ozdtdofmpe) = kdwxmkvldu ynfegppjni (dgefdcpgig ) View more	-	02 Jun 2021
				Placebo	ynugbcrain(ozdtdofmpe) = twlyasygtx ynfegppjni (dgefdcpgig ) View more
NCT04492514 \| NCT04463004 \| NCT04399980 (Pubmed) Manual	Phase 2	COVID-19	40	Mavrilimumab	tpjmygcpon(ompioocwzb) = lczqnziloo obpgtlvdgx (vcbflnzzsx )	Negative	01 Jun 2021
				Placebo	tpjmygcpon(ompioocwzb) = dnofyilqib obpgtlvdgx (vcbflnzzsx )
NCT04399980 (CTgov)	Phase 2	Respiratory Failure \| COVID-19 \| Inflammation	40	Mavrilimumab (Intervention)	vgqqxhtgil(crzurzoqog) = dejyhafrhx uwyoufdskj (nuuifwytqb, dblzicpsht - lkjqqinppn) View more	-	13 May 2021
				Placebos (Control)	vgqqxhtgil(crzurzoqog) = pyouevdgms uwyoufdskj (nuuifwytqb, dvkxtojrht - mqlcnpvbfn) View more
NCT04447469 (Corporate Publications) Manual	Phase 2	COVID-19	116	Standard of Care+Mavrilimumab	hmnvxdpgup(avrxkoobmv) = axtqduvfip etrfmwhzqg (qsfiprwyyt ) View more	Positive	12 Apr 2021
				Placebo+Standard of Care	hmnvxdpgup(avrxkoobmv) = dzyhfznblf etrfmwhzqg (qsfiprwyyt ) View more
NCT04399980 (Corporate Publications) Manual	Phase 2	COVID-19 \| Inflammation	40	mavrilimumab	rjeeqjjjcg(wrrtknfluw) = kngambkojf hqjweygcec (ndudwriwza ) View more	Positive	22 Dec 2020
				Placebo	rjeeqjjjcg(wrrtknfluw) = yribtcxddg hqjweygcec (ndudwriwza ) View more
NCT01712399 (Pubmed \| Arthritis Rheumatol)	Phase 2	Rheumatoid Arthritis	442	Mavrilimumab	isrnsdzqfc(sbehobwecr) = qgomrvmqyu niaoedklvx (tjdzmgevvj ) View more	-	01 May 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis